Equillium_Square_Logo.png
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
January 29, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
August 12, 2019 16:07 ET | Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
Equillium_Transparent-300px.png
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
December 19, 2018 08:06 ET | Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
November 15, 2018 16:07 ET | Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
effector.jpg
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
July 27, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
June 06, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
May 11, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
effector.jpg
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
April 26, 2018 07:30 ET | eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
effector.jpg
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
April 16, 2018 08:00 ET | eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...
effector.jpg
eFFECTOR Announces Appointment of John W. Smither to its Board of Directors
March 23, 2018 14:00 ET | eFFECTOR Therapeutics
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...